Danyela Darienso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Danyela Darienso has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ana Rita Pinheiro Barcessat
Graduate Program in Health Sciences—PPGCS, Federal University of Amapá—UNIFAP, Macapá 68903-419, Brazil
2 shared publications - Lucas dos Santos Nunes
Department of Biological and Health Sciences, Federal University of Amapá—UNIFAP, Macapá 68903-419, Brazil
2 shared publications - Rebeca Góes Gonçalves
Department of Biological and Health Sciences, Federal University of Amapá—UNIFAP, Macapá 68903-419, Brazil
2 shared publications - Ana Vitoria Cruz
Department of Biological and Health Sciences, Federal University of Amapá—UNIFAP, Macapá 68903-419, Brazil
1 shared publication - Chiara Rinaldi
Neurology Unit, Santo Stefano Hospital, 59100 Prato, Italy
1 shared publication - Cleuton Braga Landre
Department of Biological and Health Sciences, Federal University of Amapá—UNIFAP, Macapá 68903-419, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 June 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 937
Improving Functional Capacity and Quality of Life in Parkinson’s Disease Patients through REAC Neuromodulation Treatments for Mood and Behavioral Disorders
Parkinson’s disease is a neurological disorder that affects both motor and non-motor functions, including depression, anxiety, and cognitive decline. Currently, it remains a challenge to distinguish the correlation between these aspects and their impact on one another. To try to clarify these reciprocal influences, in this study we have used specific radio electric asymmetric conveyer (REAC) technology neuromodulation treatments for behavioral mood disorders and adjustment disorders. In particular, we employed the neuro-postural optimization (NPO) and neuro-psycho-physical optimization (NPPOs) treatments. The study enrolled randomly 50 subjects of both genders previously diagnosed with Parkinson’s disease for at least six months. Prior to and following REAC NPO and NPPOs treatments, we assessed the subjects using functional dysmetria (FD) evaluation, five times sit to stand test (FTSST) for postural stability, and the 12-item Short-Form Health Survey (SF-12) for quality of life (QLF) evaluation. The positive results produced by the REAC NPO and NPPOs neuromodulation treatments, specific for mood and adaptation disorders, on dysfunctional motor disorders, and quality of life confirm how the non-motor components can condition the symptomatology of Parkinsonian motor symptoms. These results also highlight the usefulness of REAC NPO and NPPOs treatments in improving the overall quality of life of these patients.
- 1 June 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 937
Open AccessImproving Functional Capacity and Quality of Life in Parkinson’s Disease Patients through REAC Neuromodulation Treatments for Mood and Behavioral Disorders
Parkinson’s disease is a neurological disorder that affects both motor and non-motor functions, including depression, anxiety, and cognitive decline. Currently, it remains a challenge to distinguish the correlation between these aspects and their impact on one another. To try to clarify these reciprocal influences, in this study we have used specific radio electric asymmetric conveyer (REAC) technology neuromodulation treatments for behavioral mood disorders and adjustment disorders. In particular, we employed the neuro-postural optimization (NPO) and neuro-psycho-physical optimization (NPPOs) treatments. The study enrolled randomly 50 subjects of both genders previously diagnosed with Parkinson’s disease for at least six months. Prior to and following REAC NPO and NPPOs treatments, we assessed the subjects using functional dysmetria (FD) evaluation, five times sit to stand test (FTSST) for postural stability, and the 12-item Short-Form Health Survey (SF-12) for quality of life (QLF) evaluation. The positive results produced by the REAC NPO and NPPOs neuromodulation treatments, specific for mood and adaptation disorders, on dysfunctional motor disorders, and quality of life confirm how the non-motor components can condition the symptomatology of Parkinsonian motor symptoms. These results also highlight the usefulness of REAC NPO and NPPOs treatments in improving the overall quality of life of these patients.
- Open Access
- 11 April 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (4) , 653
REAC Antalgic Neuro Modulation in Chronic Post Herpetic Neuralgia
Background: Chronic post-herpetic neuralgia (CPHN) is a symptomatic condition that afflicts adults and elderly individuals. The chronicity of this symptomatology can be conditioned by the epigenetic modifications induced by the virus on the processes of neurotransmission and sensitivity to pain. The aim of this study is to investigate whether manipulating endogenous bioelectrical activity (EBA), responsible for neurotransmission processes and contributing to the induction of epigenetic modifications, can alleviate pain symptoms. Methods: This manipulation was carried out with the antalgic neuromodulation (ANM) treatment of radioelectric asymmetric conveyer (REAC) technology. Pain assessment before and after treatment was performed using a numerical analog scale (NAS) and a simple descriptive scale (SDS). Results: The results of the analysis showed an over four-point decrease in NAS scale score and over one point decrease in SDS scale score, with a statistical significance for both tests of p < 0.005. Conclusions: The results obtained in this study demonstrate how REAC ANM manipulation of EBA can lead to improvement in epigenetically conditioned symptoms such as CPHN. These results should prompt further research to expand knowledge and ensure optimized therapeutic outcomes.
- 11 April 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (4) , 653
Open AccessREAC Antalgic Neuro Modulation in Chronic Post Herpetic Neuralgia
Background: Chronic post-herpetic neuralgia (CPHN) is a symptomatic condition that afflicts adults and elderly individuals. The chronicity of this symptomatology can be conditioned by the epigenetic modifications induced by the virus on the processes of neurotransmission and sensitivity to pain. The aim of this study is to investigate whether manipulating endogenous bioelectrical activity (EBA), responsible for neurotransmission processes and contributing to the induction of epigenetic modifications, can alleviate pain symptoms. Methods: This manipulation was carried out with the antalgic neuromodulation (ANM) treatment of radioelectric asymmetric conveyer (REAC) technology. Pain assessment before and after treatment was performed using a numerical analog scale (NAS) and a simple descriptive scale (SDS). Results: The results of the analysis showed an over four-point decrease in NAS scale score and over one point decrease in SDS scale score, with a statistical significance for both tests of p < 0.005. Conclusions: The results obtained in this study demonstrate how REAC ANM manipulation of EBA can lead to improvement in epigenetically conditioned symptoms such as CPHN. These results should prompt further research to expand knowledge and ensure optimized therapeutic outcomes.